Skip to main content
Premium Trial:

Request an Annual Quote

Cancer Institute of NJ, UW Carbone Reap $4.3M for Genomic Medicine Trial

NEW YORK (GenomeWeb News) – Investigators at the
Rutgers Cancer Institute of New Jersey (CINJ) and the University of Wisconsin Carbone Cancer Center have won a $4.3 million grant from the National Cancer Institute to conduct a clinical trial seeking to identify and use genomic biomarkers to provide targeted cancer treatments, CINJ said yesterday.

CINJ and the Carbone center have already been working together for five years to develop clinical trial protocols for NCI's Cancer Therapy Evaluation Program (CTEP), and now plan to develop new trials that may be offered through the CTEP.

The Wisconsin and New Jersey (WIN) Alliance in Precision Experimental Therapeutics partners plan to use collaborations and partnerships with other institutions to support the genomic analysis and other components of their research.

Under an existing collaboration, the partners will have access to cancer tissue samples and genomic analysis and sequencing from RUCDR Infinite Biologics, a biorepository within the Human Genetics Institute of New Jersey at Rutgers.

CINJ and the Simons Center for Systems Biology and the Institute for Advanced Study at Princeton will support the researchers' efforts to discover mutations and patterns and to interpret the results. Under another collaboration, the Rutgers School of Engineering will support an imaging component of the research program.

Under the CTEP program, the WIN Alliance will have access to patients not only in New Jersey and Wisconsin, but nationally, and there will be opportunities to expand the projects at other cancer centers around the country, CINJ said.